Cencora Inc Dossier
Qualitative Analysis
Business overview
Cencora, Inc. (formerly AmerisourceBergen Corporation) is one of the largest global pharmaceutical sourcing and distribution services companies. The company operates at the center of the healthcare supply chain, connecting pharmaceutical innovators, healthcare providers, and patients to ensure consistent access to vital therapies. Cencora is organized into two primary reportable segments: U.S. Healthcare Solutions and International Healthcare Solutions. The U.S. Healthcare Solutions segment anchors the company's growth, providing distribution services and value-added solutions to health systems, community oncologists, retail pharmacies, and physician practices, with a strong leadership position in specialty pharmaceuticals. The International Healthcare Solutions segment includes pan-European pharmaceutical distribution, global specialty logistics, and clinical trial logistics.
Research as of 29 Jul 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
A long-term investment program to strengthen Cencora's U.S. distribution network, expand capacity, and increase supply chain resilience.
Expected impact: Enhances cold chain storage capabilities and expands capacity to support the growing volume of specialty pharmaceuticals.
Accelerating the use of advanced technologies, data, and analytics to enhance customer experience and optimize global operations.
Expected impact: Improves operational efficiency, expands digital services, and supports the enterprise's digital-twin and advanced technology integrations.
Refocusing the company's portfolio on higher-margin, specialty-driven segments while shedding non-core operations.
Expected impact: Deepens Cencora's exposure to specialty oncology and retina care, moving the company closer to the point of care and driving higher-value revenue.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
Acquiring the majority of outstanding equity interests in OneOncology advances Cencora's management services organization (MSO) footprint and deepens its partnership with independent community oncology practices.
Financial impact: Expected to be approximately neutral, net of financing costs, to adjusted diluted EPS in the first 12 months following close, while contributing to long-term adjusted operating income growth.
Expands Cencora's managed services organization, Retina Consultants of America (RCA), by integrating affiliated retina physicians to deepen specialty eye care capabilities.
Financial impact: Expected to close after fiscal year 2026 ends on September 30, 2026, and to be slightly accretive to adjusted diluted EPS within the first 12 months.
Establishes the foundation of Cencora's physician-centric specialty strategy, expanding access to high-quality retina care and innovative clinical research.
Financial impact: Contributed significantly to the 22% operating income growth in the U.S. Healthcare Solutions segment during fiscal year 2025.
Strategic Partnerships
Supports the U.S. distribution of Kite's CAR T-cell therapies, Yescarta and Tecartus, extending Cencora's specialty distribution footprint in cell and gene therapies.
Terms: Not disclosed